Key result
First-line cryoballoon ablation cuts persistent AF recurrence ~58% compared with antiarrhythmic drugs.
Why the study?
Evidence supporting first-line cryoballoon ablation in treatment-naive persistent atrial fibrillation is limited.
Does first-line cryoballoon ablation reduce atrial tachyarrhythmia recurrence in treatment-naive patients with persistent atrial fibrillation compared to antiarrhythmic drug therapy?
RCT (n=320)
Open-label
1:1 centralized assignments, stratified block randomization
Yes
Does first-line cryoballoon ablation reduce atrial tachyarrhythmia recurrence in treatment-naive patients with persistent atrial fibrillation compared to antiarrhythmic drug therapy?
In treatment-naive patients with persistent atrial fibrillation, first-line cryoballoon ablation significantly reduced atrial tachyarrhythmia recurrence and improved disease-specific quality of life compared with antiarrhythmic drug therapy.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“For years, we have known that ablation is a safe and effective treatment for paroxysmal atrial fibrillation – episodes that come and go. However, there has been more skepticism regarding persistent atrial fibrillation, which does not resolve spontaneously. Several studies have shown that outcomes are generally less favorable in this group.”
Supports first-line cryoballoon ablation in treatment-naive persistent AF; extends randomized evidence beyond paroxysmal populations.
BACKGROUND AND AIMS: Evidence supporting first-line cryoballoon ablation (CBA) in treatment-naive persistent atrial fibrillation (PersAF) is limited. Consequently, we compared CBA with guideline-directed antiarrhythmic drug (AAD) therapy in this advanced form of disease. METHODS: This multicenter, prospective, randomized, open-label trial assigned 320 symptomatic, treatment-naive patients with PersAF (1:1) to CBA or AAD therapy. The primary endpoint was the first documented atrial tachyarrhythmia recurrence lasting at least 30 seconds during days 91-365. Secondary endpoints included recurrence during days 1-90 and 1-365, time-to-first recurrence, quality of life, and safety. RESULTS: In the intention-to-treat population, recurrence during days 91-365 occurred in 30/160 (18.8%) patients assigned to CBA and 71/160 (44.4%) assigned to AAD therapy (absolute difference, -25.6 percentage points; 95% confidence interval, -35.4 to -15.8; P<0.001). Supportive time-to-event analysis favored CBA (hazard ratio for AAD vs. CBA, 2.29; 95% confidence interval, 1.48-3.56; log-rank P<0.001). In CBA vs AAD comparisons, overall recurrence during days 1-365 was 23.8% vs. 55.6%, and early recurrence was 11.2% vs. 28.1% (both P<0.001; respectively). Improvement in AFEQT score was greater with CBA (17.3 vs. 6.6 points; P<0.001); whereas SF-12 component scores did not differ significantly. Adverse events recorded on event forms were infrequent in both cohorts. CONCLUSION: In selected treatment-naive patients with PersAF, first-line CBA reduced atrial tachyarrhythmia recurrence and improved disease-specific quality of life compared with AAD therapy.
No takes yet. Share an insight, caveat, or question.
凌天佑 et al. (2026) conducted an RCT in Persistent atrial fibrillation (n=320). Cryoballoon ablation vs. Antiarrhythmic drug therapy was evaluated on First documented atrial tachyarrhythmia recurrence lasting at least 30 seconds during days 91-365 (absolute difference -25.6 percentage points, 95% CI -35.4 to -15.8, p=<0.001). First-line cryoballoon ablation reduced documented atrial tachyarrhythmia recurrence by an absolute 25.6 percentage points compared with antiarrhythmic drug therapy in treatment-naive patients with persistent atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: